Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: Decision-tree analysis

Journal of Gastroenterology

Volumn 46, Issue 9, 2011, Pages 1111-1119

  Hiramatsu, Naoki ^a   Kurosaki, Masayuki ^b   Sakamoto, Naoya ^c   Iwasaki, Manabu ^d   Sakamoto, Minoru ^e   Suzuki, Yoshiyuki ^f   Sugauchi, Fuminaka ^g   Tamori, Akihiro ^h   Kakinnuma, Sei ^c   Matsuura, Kentaro ⁱ   Izumi, Namiki ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d SEIKEI UNIVERSITY   (Japan)

^e UNIVERSITY OF YAMANASHI   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g National Hospital Organization   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Chronic hepatitis C; Data mining; Decision tree; Pegylated interferon; Ribavirin; Severe anemia

Indexed keywords

CREATININE; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; REPRODUCIBILITY; RETROSPECTIVE STUDY;

ADULT; AGED; ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; COHORT STUDIES; DECISION TREES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX;

EID: 80755153562     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0412-z     Document Type: Article

References (30)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4): 1147-1171. (Pubitemid 38428955)
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13): 975-982.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001; 358(9286):958-965. (Pubitemid 32913521)
4. Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol. 2004;19:1312-7. (Pubitemid 39481767)
5. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39:668-673. (Pubitemid 39149355)
6. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G, BASL Steering Committee. Factors influencing ribavirin-induced hemolysis. J Hepatol. 2001;34:911-916. (Pubitemid 32595192)
7. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22: 555-565.
8. Lindhal K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia. J Viral Hepat. 2004;11:84-7. (Pubitemid 38221622)
9. Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis. 2004;43:140-146. (Pubitemid 38049445)
10. Hiramatsu N, Kurashige N, Oze T, Takehara T, Tamura S, Kasahara A, et al. Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res. 2008;38:52-59. (Pubitemid 350182576)
11. Oze T, Hiramatsu N, Kurashige N, Tsuda N, Yakushijin T, Kanto T, et al. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol. 2006;41:862-887.
12. Breiman LJH, Friedman RA, Olshen CJ, Stone CM. Classification and regression trees. Monterey: Wadsworth; 1980.
13. Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, et al. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol. 2005;23:4322-4329. (Pubitemid 46207005)
14. Miyaki K, Takei I, Watanabe K, Nakashima H, Omae K. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. J Epidemiol. 2002;12:243-248. (Pubitemid 44235008)
15. Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center. Surgery. 2002;132:589-602.
16. Leiter U, Buettner PG, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German Dermatological Society. J Clin Oncol. 2004;22:3660-3667. (Pubitemid 41095204)
17. Valera VA, Walter BA, Yokoyama N, Koyama Y, Iiai T, Okamoto H, et al. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. Ann Surg Oncol. 2007; 14:34-40. (Pubitemid 44954268)
18. Zlobec I, Steele R, Nigam N, Compton CC. A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. Clin Cancer Res. 2005;11:5440-5443. (Pubitemid 41060819)
19. Baquerizo A, Anselmo D, Shackleton C, Chen TW, Cao C, Weaver M, et al. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation. 2003;75: 2007-2014. (Pubitemid 36793283)
20. LeBlanc M, Crowley J. A review of tree-based prognostic models. Cancer Treat Res. 1995;75:113-124.
21. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res. 2010;40:251-260.
22. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, et al. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol. 2011;46:401-409.
23. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, et al. Sequences in the interferon sensitivitydetermining region and core region of hepatitis C virus impact pretreatment prediction of response to peg-interferon plus ribavirin: Data mining analysis. J Med Virol. 2011;83:445-452.
24. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 2011;54:439-448.
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
26. Segal MR, Bloch DA. A comparison of estimated proportional hazards models and regression trees. Stat Med. 1989;8:539-550. (Pubitemid 19116000)
27. Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, et al. Ribavirin dose reduction raises relapse rate dosedependently in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2b plus ribavirin. J Viral Hepat. 2009; 16:586-594.
28. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatits C. Nature. 2010;464:405-408.
29. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139:1181-1189.
30. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-A genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139:1190-1197.